• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Diversified Segmental Defocus Optimization Spectacles Delay Myopia in Children

By Lori Solomon HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 15, 2025.

TUESDAY, July 15, 2025 -- Daily use of diversified segmental defocus optimization (DSDO) spectacle lenses delays the onset of myopia among children, according to a study published online July 10 in JAMA Ophthalmology.

Yuchang Lu, M.D., from Peking University People’s Hospital in Beijing, and colleagues evaluated the efficacy of DSDO spectacle lenses with or without 0.01 percent atropine for myopia prevention. The analysis included children (aged 5 to 12 years) who were randomly assigned (1:1:1) to receive DSDO spectacles with placebo eye drops (DSDO group; 121 individuals), DSDO spectacles with 0.01 percent atropine eye drops (DSDOA group; 125 individuals), or single-vision spectacles with placebo eye drops (control group; 124 individuals).

The researchers found that the one-year cumulative incidence rates of myopia in the DSDO, DSDOA, and control groups were 5.8, 4.8, and 15.3 percent, respectively. The percentages of participants with fast myopic shift after one year were 15.7, 9.6, and 42.7 percent, respectively. There was significantly lower one-year cumulative myopia incidence in both the DSDO and DSDOA groups (DSDO: difference, 9.5 percent; DSDOA: difference, 10.5 percent). Results were similar for the percentage of patients with fast myopic shift (DSDO: difference, 27.0 percent; DSDOA: difference, 33.1 percent) compared with the control group. There were no significant differences between the DSDO and DSDOA groups.

"The daily use of DSDO spectacle lenses delayed the onset of myopia and slowed its progression among children without myopia; thus, the use of these lenses might be an effective alternative preventive method for myopia in children without myopia," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted July 2025

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.